17 Mar 2026 | 5 Mins Read
AstraZeneca gets Imfinzi approval for liver cancer treatment
Flipitmoney
AstraZeneca Pharma India Ltd secured CDSCO approval to market Durvalumab (Imfinzi) for unresectable hepatocellular carcinoma patients not receiving prior systemic therapy. The expanded indication targets liver cancer patients ineligible for surgery. This approval enables Imfinzi commercialization in India, strengthening AstraZeneca's oncology portfolio.